<DOC>
	<DOCNO>NCT00129311</DOCNO>
	<brief_summary>Despite widespread use nicotine replacement therapy treatment nicotine dependence , many smoker still unable quit smoking . The purpose study determine safety effectiveness selegiline aid help smoker quit smoking .</brief_summary>
	<brief_title>Usefulness Selegiline Aid Quit Smoking - 1</brief_title>
	<detailed_description>Despite availability nicotine replacement therapy sustained-relapse bupropion treatment nicotine dependence , still significant proportion cigarette smoker unable quit smoking . Therefore , new effective pharmacotherapies smoke cessation need . The primary aim study determine safety efficacy selegiline aid smoking cessation . In study , 200 nicotine-dependent cigarette smoker participate 8-week , double-blind , placebo-controlled trial follow 4 year . Participants randomly assign receive either selegiline placebo . Selegiline dose 5 mg take day first week . This increase 5 mg twice daily remain 7 week . The target smoke `` quit date '' Day 15 . All smoker receive brief weekly manualized smoking cessation counsel Mayo Clinic 's `` Smoke Free Livin ' It '' program . The primary smoking cessation outcome measure 7-day point prevalence smoke abstinence 6-month follow-up . Secondary cessation outcome measure include continuous smoke abstinence last four week trial ( Days 29-56 ) 7-day point prevalence abstinence end 8-week trial ( Days 49-56 ) .</detailed_description>
	<criteria>Meets DSMIV criterion nicotine dependence Fagerstrom Test Nicotine Dependence ( FTND ) score great 5 Smokes least 15 cigarette daily ( average 1 week , within month prior enrollment ) Motivated quit smoking within 30 day time initial evaluation At least one unsuccessful attempt quit smoking past year An expired breath CO level great 10 ppm baseline plasma cotinine level great 150 ng/ml initial evaluation Body weight least 100 lb Avoidance nicotine replacement product use one month prior enrollment Speaks English Currently take overthecounter prescription sympathomimetic agent ( e.g. , pseudoephedrine , methylphenidate ) , antidepressant agent ( e.g. , tricyclic antidepressant , serotonin reuptake inhibitor , bupropion , monoamine oxidase inhibitor ) , meperidine ( Demerol ) Serious medical disorder unstable angina liver failure Abnormalities baseline bloodwork ( e.g. , threefold elevation liver function test , electrolyte abnormality ) Physiologically dependent and/or abuse alcohol drug abuse ( e.g. , cocaine , opiates , benzodiazepine , etc . ) 6 month prior enrollment ( base clinical evaluation , include selfreport , confirm positive urine toxicology screen ) Meets DSMIV criterion current diagnosis major depressive disorder , panic disorder , posttraumatic stress disorder Current past history bipolar disorder schizophrenia Past history major depression associate historical evidence suicidal homicidal behavior , psychotic symptom Currently reside another study participant Presence suicidal homicidal ideation Significant impairment social occupational functioning , either time initial evaluation trial Known hypersensitivity selegiline hydrochloride</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Tobacco</keyword>
</DOC>